Pasteurella haemolytica leukotoxin induces bovine leukocytes to undergo morphologic changes consistent with apoptosis in vitro.
Infection of the bovine lung with Pasteurella haemolytica results in an acute respiratory disorder known as pneumonic pasteurellosis. One of the key virulence determinants used by this bacterium is secretion of an exotoxin that is specific for ruminant leukocytes (leukotoxin). At low concentrations, the leukotoxin can activate ruminant leukocytes, whereas at higher concentrations, it inhibits leukocyte functions and is cytolytic, presumably as a result of pore formation and subsequent membrane permeabilization. We have investigated the possibility that the activation-inhibition paradox is explained in part by leukotoxin-mediated apoptosis (i.e., activation-induced cell death) of bovine leukocytes. Incubation of bovine leukocytes with P. haemolytica leukotoxin caused marked cytoplasmic membrane blebbing (zeiosis) and chromatin condensation and margination, both of which are hallmarks of apoptosis. The observed morphologic changes in bovine leukocytes were leukotoxin dependent, because they were significantly diminished in the presence of an anti-leukotoxin monoclonal antibody. In addition, bovine leukocytes incubated with culture supernatant from a mutant strain of P. haemolytica that does not produce any detectable leukotoxin failed to exhibit the morphologic changes characteristic of cells undergoing apoptosis. These observations may represent an important mechanism by which P. haemolytica overwhelms host defenses, contributing to the fibrinous pleuropneumonia characteristic of bovine pasteurellosis.
Stevens
P K
PK
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison 53706, USA.
Czuprynski
C J
CJ
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors / Q000633:toxicity*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002417:Cattle; D002462:Cell Membrane / Q000187:drug effects / Q000473:pathology; D002467:Cell Nucleus / Q000187:drug effects / Q000473:pathology; D003603:Cytotoxins / Q000037:antagonists & inhibitors / Q000633:toxicity*; D005098:Exotoxins / Q000037:antagonists & inhibitors / Q000633:toxicity*; D066298:In Vitro Techniques; D007962:Leukocytes / Q000187:drug effects* / Q000473:pathology*; D016978:Mannheimia haemolytica / Q000235:genetics / Q000472:pathogenicity*; D009154:Mutation; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D012766:Pasteurellosis, Pneumonic / Q000209:etiology / Q000473:pathology; D011433:Propranolol / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000911:Antibodies, Monoclonal; D001427:Bacterial Toxins; D002121:Calcium Channel Blockers; D003603:Cytotoxins; D005098:Exotoxins; C018579:leukotoxin; D011433:Propranolol; D014700:Verapamil